SLC5A2 and type 2 diabetes mellitus: Cardiovascular outcomes trials have demonstrated the efficacy of sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing risk of adverse cardiovascular events in patients with T2D and high cardiovascular risk (ADA and 9, 2021).